HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
北海道大学病院  >
雑誌発表論文等  >

HB Vaccination in the Prevention of Viral Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Previous HBV Infection

フルテキスト
14-11_p1226-1230.pdf148.06 kBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/38729

タイトル: HB Vaccination in the Prevention of Viral Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Previous HBV Infection
その他のタイトル: HB vaccine to prevent viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection
著者: Onozawa, Masahiro 著作を一覧する
Hashino, Satoshi 著作を一覧する
Darmanin, Stephanie 著作を一覧する
Okada, Kohei 著作を一覧する
Morita, Rena 著作を一覧する
Takahata, Mutsumi 著作を一覧する
Shigematsu, Akio 著作を一覧する
Kahata, Kaoru 著作を一覧する
Kondo, Takeshi 著作を一覧する
Tanaka, Junji 著作を一覧する
Imamura, Masahiro 著作を一覧する
Asaka, Masahiro 著作を一覧する
キーワード: hepatitis B virus
reverse seroconversion
reactivation of hepatitis
vaccination
recombinant hepatitis B vaccine
発行日: 2008年11月
出版者: Elsevier Inc.
誌名: Biology of Blood and Marrow Transplantation
巻: 14
号: 11
開始ページ: 1226
終了ページ: 1230
出版社 DOI: 10.1016/j.bbmt.2008.08.007
抄録: HBV-reverse seroconversion (RS) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a frequent late-onset complication in recipients with previous HBV infection. We conducted post-transplant HB vaccine intervention in 38 allo-HSCT recipients with previous HBV infection. Firstly, we followed the recipients without any intervention (historical control) until 2003; hence we commenced HB vaccination. Out of the patients who underwent transplantation after 2003, 13 recipients were immunized by a standard 3-dose regimen after immunosuppressant cessation (vaccine group), while 12 recipients were observed without any intervention (non-vaccine group). Eight of the 13 historical control group recipients and 3 of the 12 non-vaccine group recipients, but none of the 13 vaccine group recipients, suffered HBV-RS. Cumulative risks of HBV-RS at 3 years post-HSCT in the historical control, non-vaccine and vaccine groups were 41%, 39% and 0% respectively (P = 0.022). We therefore conclude that intervention with HB vaccines is significantly effective in preventing post-HSCT HBV-RS.
資料タイプ: article (author version)
URI: http://hdl.handle.net/2115/38729
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 小野澤 真弘

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学